Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


American College of Cardiology Meeting In Brief: DuPont Merck's Coumadin

Executive Summary

DuPont Merck's Coumadin: Subset analysis of the 6,797-patient Studies of Left Ventricular Dysfunction (SOLVD) trial shows that warfarin users had a statistically significant 24% reduction in risk of all-cause mortality compared to patients who did not concomitantly receive warfarin during the course of the trial, Ayman Al-Khadra, MD, New England Medical Center, Boston, reported March 26. There was a 28% risk reduction for cardiovascular death and an 18% risk reduction for mortality or hospitalization for heart failure associated with warfarin use...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts